TY - JOUR
T1 - Warfarin
T2 - An inconvenient truth
AU - Gattellari, Melina
AU - Worthington, John
AU - Zwar, Nicholas
PY - 2009/1/1
Y1 - 2009/1/1
N2 - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.
AB - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.
UR - http://www.scopus.com/inward/record.url?scp=60549093415&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.108.527903
DO - 10.1161/STROKEAHA.108.527903
M3 - Editorial
C2 - 18757283
AN - SCOPUS:60549093415
SN - 0039-2499
VL - 40
SP - 5
EP - 7
JO - Stroke
JF - Stroke
IS - 1
ER -